CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40181544/
Despite recent U.S. Food and Drug Administration (FDA) approval of multiple therapies for patients with acute myeloid leukemia (AML), clinical outcomes for those patients continue to remain poor. There are...
This review examines advances in CAR-T therapy for acute myeloid leukemia, highlighting challenges including lack of AML-specific antigens and an immunosuppressive marrow microenvironment, while summarizing ongoing clinical trials exploring feasibility, efficacy, and resistance mechanisms.
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39913928/
Fitness assessment in patients with acute myeloid leukemia (AML) is critical to deliver the right therapy to the right patient. Although several scoring systems are available to aid in determining...
AML fitness assessment should be individualized, not binary, integrating clinical status, treatment goals, quality of life, patient preferences, and social factors to guide optimal therapy selection in evolving treatment landscapes.
Novel classification system and high-risk categories of pediatric acute myeloid leukemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39781610/
The prognosis of pediatric acute myeloid leukemia (AML) remains poor compared with pediatric acute lymphoblastic leukemia (ALL); accurate diagnosis and treatment strategies based on the genomic background are urgently needed....
Review proposes genomics-based pediatric AML classification, identifying novel high-risk subtypes (e.g., BCL11B, UBTF-TD) with distinct biology, enabling improved risk stratification, prognosis prediction, and development of targeted therapeutic strategies.
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/40332046/
The prognosis for relapsed or refractory (R/R) nucleophosmin 1-mutated (NPM1m) acute myeloid leukemia (AML) is poor and represents an urgent unmet medical need. Revumenib, a potent, selective menin inhibitor, was...
Revumenib shows meaningful clinical responses in relapsed/refractory NPM1-mutated AML, achieving remissions enabling stem cell transplant with manageable safety, addressing an unmet need in heavily pretreated patients.
Neutropenic Tonsillar Ulcer as the Initial Presentation of Acute Myeloid Leukemia in a Young Woman: A Case Report - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/41948273/
Neutropenic ulceration can represent the initial presentation of acute myeloid leukemia (AML), but diagnostic delay may occur when recurrent oral ulcers in young adults are attributed to benign causes. We...
Case report highlights neutropenic tonsillar ulcer as initial AML presentation, emphasizing diagnostic delays, importance of repeated hematologic evaluation, and need to consider malignancy in persistent, atypical oral ulcers with neutropenia.